Although the remoteness of these areas made it difficult for responders to gain access, it also helped to prevent the spread of the virus, says Henry Kyobe Bosa, who leads the Ebola and COVID-19 response for Uganda’s Ministry of Health.
Vaccine roll-out and treatment with a monoclonal antibody therapy both began soon after the outbreak was declared, which helped to prevent serious illness. “We are improving in the management, the response, the community engagement and the contact tracing”, says Bosa.
New malaria drugs
In November, the World Health Organization (WHO) approved the first malaria treatment for infants. Given that, currently, children under the age of five account for around 75% of malaria deaths globally, the medicine could bring the world one step closer to eliminating the disease.
An infant version of the treatment, called Coartem (artemether–lumefantrine), “provides a drug formulation that can now be safely used to treat malaria in the relatively neglected population of babies and young infants”, says Jane Achan, a paediatrician who specializes in infectious diseases and is principal adviser at the Malaria Consortium in London. “It most definitely will have wide implications, especially in improving treatment of malaria in the populations at risk, and also improving treatment outcomes among babies and young infants and in settings with drug-resistant malaria parasites,” she adds.
In a phase III clinical trial this year, a second malaria drug, called ganaplacide–lumefantrine (GanLum), successfully treated malaria in 97.4% of participants. GanLum also cleared parasites that have developed resistance to the antimalarial drug artemisinin.
If GanLum receives regulatory approval, it will be the first new class of malaria medicine in more than 25 years.
Peanut allergies plummet
A study showed that peanut allergies in children have fallen in the United States in the past decade, in a major victory for science-based policy and decision-making5. For years, parents were told not to expose their babies to peanuts to prevent dangerous allergic reactions. But a landmark study6 in 2015 found the opposite to be true — when infants are introduced to peanut products as early as four months old, they are much less likely to become allergic to them. The study led to a change in health guidelines between 2015 and 2017.
Now, there has been a 43% decrease in peanut-allergy prevalence in children under three in the United States, compared with 2012. The same method of exposing infants to a variety of allergens also led to a 36% reduction in other food allergies. “This is a good year to have a peanut allergy or a food allergy,” says Michael Pistiner, a paediatric allergist at Mass General Brigham for Children in Boston, Massachusetts. “So much of our field has been witnessing changes for the better, this particular year has been exciting.”
“This is a great example of translating controlled trial findings into broader community level outcomes,” Pistiner says.